While blood pressure control and “disease-modifying” agents, such as renin–angiotensin–aldosterone system (RAAS) inhibitors and sodium-glucose cotransporter-2 (SGLT2) inhibitors, reduce the risk of kidney failure, dietary strategies to prevent CKD progression are a current patient-prioritised area of research inquiry [13]. This evidence concerns the gene SLC5A2 and chronic kidney disease.